Jacobs Levy Equity Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Jacobs Levy Equity Management’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-79,700	Closed	-$279K	–	1096
2018 Q4	$279K	Buy	+79,700	New	+$554K	﹤0.01%	821
2017 Q4	–	Sell	-14,640	Closed	-$130K	–	1107
2017 Q3	$130K	Buy	+14,640	New	+$151K	﹤0.01%	910
2017 Q2	–	Sell	-19,080	Closed	-$201K	–	1066
2017 Q1	$201K	Buy	+19,080	New	+$203K	﹤0.01%	798
2014 Q2	–	Sell	-33,900	Closed	-$702K	–	980
2014 Q1	$702K	Sell	33,900 -14,370	-30%	-$285K	0.01%	613
2013 Q4	$623K	Buy	48,270 +19,170	+66%	+$266K	0.01%	672
2013 Q3	$339K	Buy	+29,100	New	+$239K	0.01%	768

Other funds holding INSY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Jacobs Levy Equity Management's INSY Position: Q1 2019 in Review

Jacobs Levy Equity Management sold out of Insys Therapeutics, Inc. (INSY) in Q1 2019, closing a stake of 79,700 shares — an estimated $279K sold.

Jacobs Levy Equity Management first reported a position in INSY in Q3 2013 and held it in 6 quarters. The position peaked at $702K in Q1 2014. 98 funds tracked by Wall St. Rank hold INSY as of Q1 2019.

Jacobs Levy Equity Management reported no remaining Insys Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
Jacobs Levy Equity Management sold 79,700 Insys Therapeutics, Inc. shares in Q1 2019, an estimated $279K.
Jacobs Levy Equity Management first reported a position in Insys Therapeutics, Inc. in Q3 2013 and held it in 6 quarters.
Jacobs Levy Equity Management's Insys Therapeutics, Inc. position peaked at $702K in Q1 2014.
98 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2019.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2019, filed 14 May 2019.